Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma

  • STATUS
    Recruiting
  • End date
    Jun 3, 2023
  • participants needed
    34
  • sponsor
    Daniela A. Bota
Updated on 27 February 2022
platelet count
growth factor
karnofsky performance status
flair
neutrophil count
bevacizumab
anaplastic astrocytoma
astrocytoma, anaplastic

Summary

This is a Phase 2 study in subjects with WHO Grade III Anaplastic Astrocytoma (G3 astrocytoma) who had progressive disease during first or second line treatment and who have not previously received any BEV or any experimental agents.

Description

Primary Objective:

The primary objective will be to determine the efficacy of NOVOTTF-200A in recurrent anaplastic astrocytoma patients (6-month progression-free survival)

Secondary Objectives:

  • To evaluate the safety of NOVOTTF-200A in the subject population.
  • To evaluate efficacy of NOVOTTF-200A in the subject population.
  • To see if the presence of ATRX, TERT promoter, IDH1 mutations and/or MGMT promoter methylation, confers a better response to NOVOTTF-200A.
  • To determine if the treatment significantly modifies the patient's quality of life. Sponsor will use the Functional Assessment of Cancer Therapy (FACT) questionnaires:
  • FACT-Brain (FACT-Br)
  • FACT-Cognitive Function (FACT-Cog)

Exploratory Objectives:

  • To determine if the presence of proneural or mesenchymal phenotype (Cytoscan analysis) confers a better response to NovoTTF.
  • To determine if the in vitro sensitivity of the glioma cells derived from patient specimens before and after the NOVOTTF-200A treatment correlates with the patient's response to treatment.

Details
Condition Astrocytoma, Grade III
Treatment NovoTTF-200A
Clinical Study IdentifierNCT03450850
SponsorDaniela A. Bota
Last Modified on27 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Understand and voluntarily sign and date an informed consent document before any study related assessments/procedures are conducted
Males and females of age 18 years at the time of the signing of the informed consent document
All subjects must have histologic evidence of G3 MG and radiographic evidence of recurrence or disease progression (defined as either a greater than 25% increase in the largest bi-dimensional product of enhancement, a new enhancing lesion or a significant increase in T2 FLAIR)
Subjects with archival tumor tissue suitable for genetic testing must give permission to access and test the tissue; subjects without archival tumor tissue are eligible
No prior treatment with BEV or any anti-angiogenesis agents
At least 4 weeks from surgical resection and 12 weeks from end of radiotherapy prior to enrollment in this study, unless relapse is confirmed by tumor biopsy or new lesion outside of radiation field, or if there are two MRIs confirming progressive disease that are 8 weeks apart
All AEs resulting from prior chemotherapy, surgery or radiotherapy must have resolved to NCI-CTCAE (v. 4.03) Grade 1 (except for laboratory parameters outlined below)
Laboratory results within 7 days prior to NOVOTTF-200A administration (transfusions and/or growth factor support may be used at the discretion of the Investigator during Screening)
Hemoglobin 9 g/dL
Absolute neutrophil count (ANC) 1.5 109/L
Platelet count 100 109/L
Serum bilirubin 1.5 upper limit of normal (ULN) or 3 ULN if Gilbert's disease is documented
Aspartate transaminase (AST) 2.5 ULN
Serum creatinine 1.5 ULN
Karnofsky Performance Status (KPS) score 70%
Willing and able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria

The presence of any of the following will exclude a subject from enrollment
The presence of 1p19q LOH which is diagnostic for anaplastic oligodendroglioma (AO)
Co-medication that may interfere with study results, e.g., immunosuppressive agents other than corticosteroids. (Steroid therapy for control of cerebral edema is allowed at the discretion of the investigator. Subjects should be on a stable dose of steroids for at least 1 week prior to study beginning.)
Chemotherapy administered within 4 weeks (6 weeks for an IV nitrosoureas and 12 weeks for an implanted nitrosoureas wafer) prior to Day 1 of study treatment
Pregnancy or breastfeeding
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics & psychiatric illness/social situations that would limit adherence with study requirements, or disorders associated with significant immunocompromised state
Known previous/current malignancy requiring treatment within 3 years except for cervical carcinoma in situ, squamous or basal cell skin carcinoma and superficial bladder carcinoma
Any comorbid condition that confounds the ability to interpret data from the study as judged by the Investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note